Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways
The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Abstract
RNA interference (RNAi) is a universal and evolutionarily conserved phenomenon of post-transcriptional gene silencing by means of sequence-specific mRNA degradation, triggered by small double-stranded RNAs. Because this mechanism can be efficiently induced in vivo by expressing target-complementary short hairpin RNA (shRNA) from non-viral and viral vectors, RNAi is attractive for functional genomics and human therapeutics. Here we systematically investigate the long-term effects of sustained high-level shRNA expression in livers of adult mice. Robust shRNA expression in all the hepatocytes after intravenous infusion was achieved with an optimized shRNA delivery vector based on duplex-DNA-containing adeno-associated virus type 8 (AAV8). An evaluation of 49 distinct AAV/shRNA vectors, unique in length and sequence and directed against six targets, showed that 36 resulted in dose-dependent liver injury, with 23 ultimately causing death. Morbidity was associated with the downregulation of liver-derived microRNAs (miRNAs), indicating possible competition of the latter with shRNAs for limiting cellular factors required for the processing of various small RNAs. In vitro and in vivo shRNA transfection studies implied that one such factor, shared by the shRNA/miRNA pathways and readily saturated, is the nuclear karyopherin exportin-5. Our findings have fundamental consequences for future RNAi-based strategies in animals and humans, because controlling intracellular shRNA expression le…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cellular toxicity can, for example, be observed in rAAV shRNA overexpression studies in which ubiquitous promoters were used that caused saturation of cellular miRNA pathways [88].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [88]
In the citing paper
“However, the relatively large size, the requirement that the transcript starts with a G or A, the sometimes too active transcription, and the sensitivity to specific cellular profiles make the human U6 promoter a less versatile promoter [88,131,132].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [88]
In the citing paper
“Consistent with this possibility, when multiple miRNAs are packaged within a single construct, they may compete for processing by the cellular miRNA biogenesis machinery, leading to reduced efficiency in individual miRNA maturation and function 44,45 .”
From rAAV-mediated Multi-miRNA Delivery Targeting MAPK Pathway Suppresses Laser-induced Choroidal Neovascularization in Mice (2026) · cites this paper as [44]
Citations
Cites
Bartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
The functions of animal microRNAs
Ambros, V. (2004) · Nature · doi:10.1038/nature02871 · Cited by 10,728
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949
Hannon, G. J. (2002) · Nature · doi:10.1038/418244a · Cited by 3,538
Identification of tissue-specific microRNAs from mouse
Lagos-Quintana, M., Rauhut, R., Yalcin, A., Meyer, J., Lendeckel, W., & Tuschl, T. (2002) · Current Biology · doi:10.1016/s0960-9822(02)00809-6 · Cited by 3,355
Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs
Yi, R., Qin, Y., Macara, I. G., & Cullen, B. R. (2003) · Genes & Development · doi:10.1101/gad.1158803 · Cited by 3,010
Nuclear Export of MicroRNA Precursors
Lund, E., Güttinger, S., Calado, A., Dahlberg, J. E., & Kutay, U. (2004) · Science · doi:10.1126/science.1090599 · Cited by 2,714
Mechanisms of gene silencing by double-stranded RNA
Meister, G., & Tuschl, T. (2004) · Nature · doi:10.1038/nature02873 · Cited by 2,539
Modulation of Hepatitis C Virus RNA Abundance by a Liver-Specific MicroRNA
Jopling, C. L., Yi, M., Lancaster, A. M., Lemon, S. M., & Sarnow, P. (2005) · Science · doi:10.1126/science.1113329 · Cited by 2,521
Self-citationExportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs
BOHNSACK, M. T., CZAPLINSKI, K., & GÖRLICH, D. (2004) · RNA · doi:10.1261/rna.5167604 · Cited by 1,433
Cited by
Knocking down barriers: advances in siRNA delivery
Whitehead, K. A., Langer, R., & Anderson, D. G. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2742 · Cited by 3,115
“This shortcut reduces the potential for an innate immune interferon response and the shutdown of cellular protein expression that can occur following the interaction of long pieces (>30 nucleotides) of doublestranded RNA with intracellular RNA receptors 10 .”
BackgroundAdeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
Advances in oligonucleotide drug delivery
Roberts, T. C., Langer, R., & Wood, M. J. A. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0075-7 · Cited by 2,027
MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review
Iorio, M. V., & Croce, C. M. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201100209 · Cited by 1,739
“In addition, exceed-ingly high levels of shRNA expression increase the probability of off-target silencing, elicit non-specific effects such as interferon response and can also saturate Exportin5 pathway of endogenous miRNAs with fatal consequences (Grimm et al, 2006).”
Di Leva, G., Garofalo, M., & Croce, C. M. (2014) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012513-104715 · Cited by 1,672
“Beyond the RISC saturation effects described by Grimm and coworkers (148), there is the potential to induce unwanted effects when novel miRNAs are introduced into a cell.”
BackgroundNoncoding RNA therapeutics—Challenges and potential solutions
Winkle, M., El-Daly, S. M., Fabbri, M., & Calin, G. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00219-z · Cited by 1,551
Lee, Y. S., & Dutta, A. (2009) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.4.110807.092222 · Cited by 1,505
Targeting microRNAs in cancer: rationale, strategies and challenges
Garzon, R., Marcucci, G., & Croce, C. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3179 · Cited by 1,493
“Grim and colleagues elegantly showed that sustained high expression of short hairpin RNAs by AAV vectors induced severe dose-dependent liver damage, owing to interference with endogenous miRNA processing in the liver and resulting in liver-specific miRNA downregulation and injur”
Therapeutic microRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model
Kota, J., Chivukula, R. R., O'Donnell, K. A., Wentzel, E. A., Montgomery, C. L., Hwang, H.-W., Chang, T.-C., Vivekanandan, P., Torbenson, M., Clark, K. R., et al. (2009) · Cell · doi:10.1016/j.cell.2009.04.021 · Cited by 1,452
“Finally, it has been previously shown that the miRNA biogenesis pathway can be competitively inhibited by the expression of certain shRNAs, resulting in toxic effects following delivery of these transcripts (Grimm et al., 2006).”
InfluentialBennett, C. F., & Swayze, E. E. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105654 · Cited by 1,374
The promises and pitfalls of RNA-interference-based therapeutics
Castanotto, D., & Rossi, J. J. (2009) · Nature · doi:10.1038/nature07758 · Cited by 1,221
“Exogenously introduced dsRNA sequences can sequester components that make up the cellular machinery involved in gene silencing (see page 396 ), thereby reducing the accessibility of the machinery to a class of small RNAs known as microRNAs (miRNAs) that are entering the natural cellular pathwa”
Interfering with disease: a progress report on siRNA-based therapeutics
de Fougerolles, A., Vornlocher, H.-P., Maraganore, J., & Lieberman, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2310 · Cited by 1,203
“As a consequence, siRNAs are the class of RNAi therapeutics that are most advanced in preclinical and clinical studies.”
BackgroundJackson, A. L., & Linsley, P. S. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3010 · Cited by 1,083
“Sustained high-level expression of shRNAs in the liver of adult mice can lead to lethalit”
BackgroundRNAi therapeutics: a potential new class of pharmaceutical drugs
Bumcrot, D., Manoharan, M., Koteliansky, V., & Sah, D. W. Y. (2006) · Nature Chemical Biology · doi:10.1038/nchembio839 · Cited by 1,085
“Although viral delivery provides the potential advantage that a single administration could lead to durable down-modulation of the targeted pathological protein, a major risk was highlighted recently 81 .”
BackgroundsiRNA versus miRNA as therapeutics for gene silencing
Lam, J. K. W., Chow, M. Y. T., Zhang, Y., & Leung, S. W. S. (2015) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2015.23 · Cited by 1,081
Non‐coding RNAs: regulators of disease
Taft, R. J., Pang, K. C., Mercer, T. R., Dinger, M., & Mattick, J. S. (2010) · The Journal of Pathology · doi:10.1002/path.2638 · Cited by 1,058
Strategies for silencing human disease using RNA interference
Kim, D. H., & Rossi, J. J. (2007) · Nature Reviews Genetics · doi:10.1038/nrg2006 · Cited by 1,078
“and saturation of endogenous RNAi pathway component”
MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy
Kasinski, A. L., & Slack, F. J. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3166 · Cited by 936
“Previous reports suggest that the functions of two key miRNA silencing components, exportin 5 and Argonaute 2, are diminished when miRNA or siRNA levels are elevate”
Chemistry, structure and function of approved oligonucleotide therapeutics
Egli, M., & Manoharan, M. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad067 · Cited by 828
RNAi therapeutics: Principles, prospects and challenges
Aagaard, L., & Rossi, J. J. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.03.005 · Cited by 895
“In their work Grimm et al [51] observed fatality in mice that had received high doses of liver-directed AAV-encoded shRNAs.”
BackgroundTherapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges
Mingozzi, F., & High, K. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2988 · Cited by 893
Kosik, K. S. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn2037 · Cited by 826
“Recent data suggest that exogenous siRNAs can overwhelm miRNA processin”
BackgroundRNA interference in the clinic: challenges and future directions
Pecot, C. V., Calin, G. A., Coleman, R. L., Lopez-Berestein, G., & Sood, A. K. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2966 · Cited by 820
“Additionally, other investigators have shown that the high-level expression of short hairpin RNAs in the livers of mice overwhelmed the hepatic RNAi processing machinery, causing hepatic failure and deat”
BackgroundMammalian microRNAs: experimental evaluation of novel and previously annotated genes
Chiang, H. R., Schoenfeld, L. W., Ruby, J. G., Auyeung, V. C., Spies, N., Baek, D., Johnston, W. K., Russ, C., Luo, S., Babiarz, J. E., et al. (2010) · Genes & Development · doi:10.1101/gad.1884710 · Cited by 825
“The level of mmu-miR-1224, an annotated mirtronic miRNA (Berezikov et al. 2007), increased in the presence of TNdrosha, as expected if this pre-miRNA had more access to Exportin-5 and Dicer when the canonical pre-miRNAs were reduced (Grimm et al. 2006).”
BackgroundDelivery of siRNA Therapeutics: Barriers and Carriers
Wang, J., Lu, Z., Wientjes, M. G., & Au, J. L.-S. (2010) · The AAPS Journal · doi:10.1208/s12248-010-9210-4 · Cited by 798
“The latter, in turn, can lead to toxicity, e.g., liver toxicity in mice receiving high doses of liver-directed AAV-encoded shRNA ( 18 ).”
BackgroundA skin microRNA promotes differentiation by repressing ‘stemness’
Yi, R., Poy, M. N., Stoffel, M., & Fuchs, E. (2008) · Nature · doi:10.1038/nature06642 · Cited by 790
Current prospects for RNA interference-based therapies
Davidson, B. L., & McCray, P. B. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2968 · Cited by 761
“Reduced shRNA export could cause nuclear accumulation and toxicity 63, 64 .”
BackgroundTransgenerational epigenetic programming via sperm microRNA recapitulates effects of paternal stress
Rodgers, A. B., Morgan, C. P., Leu, N. A., & Bale, T. L. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1508347112 · Cited by 751
An Optimized microRNA Backbone for Effective Single-Copy RNAi
Fellmann, C., Hoffmann, T., Sridhar, V., Hopfgartner, B., Muhar, M., Roth, M., Lai, D. Y., Barbosa, I. A. M., Kwon, J. S., Guan, Y., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.11.020 · Cited by 719
“, 2011), these results demonstrate that single-copy expression of miR-E-based shRNAs has no major effects on endogenous miRNA biogenesis and thus provides a validated approach for minimizing toxicities associated with shRNA expression in other RNAi systems (Castanotto et al., 2007; Grimm et al., 2006).”
BackgroundHuman tRNA-derived small RNAs in the global regulation of RNA silencing
Haussecker, D., Huang, Y., Lau, A., Parameswaran, P., Fire, A. Z., & Kay, M. A. (2010) · RNA · doi:10.1261/rna.2000810 · Cited by 713
“The FLAG-Ago2 PAZ deletion mutant in Figure 7 was generated according to Gu et al. (2009).”
MethodSelf-citationDicer, Drosha, and Outcomes in Patients with Ovarian Cancer
Merritt, W. M., Lin, Y. G., Han, L. Y., Kamat, A. A., Spannuth, W. A., Schmandt, R., Urbauer, D., Pennacchio, L. A., Cheng, J.-F., Nick, A. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0803785 · Cited by 712
siRNA vs. shRNA: Similarities and differences
Rao, D. D., Vorhies, J. S., Senzer, N., & Nemunaitis, J. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.04.004 · Cited by 660
“The degree of miRNA downregulation was related neither to the shRNA sequence nor to the degree of downregulation of the target mRNA [209].”
BackgroundState-of-the-art gene-based therapies: the road ahead
Kay, M. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2971 · Cited by 666
Self-citationGrimm, D., Lee, J. S., Wang, L., Desai, T., Akache, B., Storm, T. A., & Kay, M. A. (2008) · Journal of Virology · doi:10.1128/jvi.00254-08 · Cited by 696
Self-citationRNA-based therapeutics: an overview and prospectus
Zhu, Y., Zhu, L., Wang, X., & Jin, H. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-05075-2 · Cited by 623
“In addition, off-target binding [162], sequence-induced toxicity, and oversaturation of the endogenous RNA processing pathway [163] affect the effectiveness of RNA-based approaches.”
BackgroundNotch Promotes Radioresistance of Glioma Stem Cells
Wang, J., Wakeman, T. P., Lathia, J. D., Hjelmeland, A. B., Wang, X.-F., White, R. R., Rich, J. N., & Sullenger, B. A. (2010) · Stem Cells · doi:10.1002/stem.261 · Cited by 656
Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes
Rozema, D. B., Lewis, D. L., Wakefield, D. H., Wong, S. C., Klein, J. J., Roesch, P. L., Bertin, S. L., Reppen, T. W., Chu, Q., Blokhin, A. V., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703778104 · Cited by 658
Coordinate Suppression of ERBB2 and ERBB3 by Enforced Expression of Micro-RNA miR-125a or miR-125b
Scott, G. K., Goga, A., Bhaumik, D., Berger, C. E., Sullivan, C. S., & Benz, C. C. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m609383200 · Cited by 646
Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs
Shen, X., & Corey, D. R. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1239 · Cited by 632
Breaking down the barriers: siRNA delivery and endosome escape
Dominska, M., & Dykxhoorn, D. M. (2010) · Journal of Cell Science · doi:10.1242/jcs.066399 · Cited by 630
“Although it is effective, the stable overexpression of shRNAs has, in some cases, been associated with cytotoxic effects resulting from outcompetition of endogenous molecules for limited amounts of RNAi pathway components (An et al., 2006; Grimm et al., 2006).”
BackgroundMcBride, J. L., Boudreau, R. L., Harper, S. Q., Staber, P. D., Monteys, A. M., Martins, I., Gilmore, B. L., Burstein, H., Peluso, R. W., Polisky, B., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801775105 · Cited by 607
“Similar to our work, Grimm and colleagues (15) observed acute liver toxicity and mortality in mice after systemic shRNA delivery, which correlated with increased mature antisense RNA levels.”
BackgroundPosttranscriptional Regulation of MicroRNA Biogenesis in Animals
Siomi, H., & Siomi, M. C. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.03.013 · Cited by 578
“Once processed, pre-miRNAs are transported to the cytoplasm by Exportin-5, which appears to be limiting (Grimm et al., 2006; Diederichs et al., 2008).”
BackgroundT Cell-Specific siRNA Delivery Suppresses HIV-1 Infection in Humanized Mice
Kumar, P., Ban, H.-S., Kim, S.-S., Wu, H., Pearson, T., Greiner, D. L., Laouar, A., Yao, J., Haridas, V., Habiro, K., et al. (2008) · Cell · doi:10.1016/j.cell.2008.06.034 · Cited by 570
“Although overexpression of shRNA in vivo has been reported to affect miRNA biogenesis and function, leading to lethality in mice (Grimm et al., 2006), a recent study suggests that repeated administration of synthetic siRNA targeting the liver did not affect liver-specific miRNA expression or…”
Brown, B. D., Gentner, B., Cantore, A., Colleoni, S., Amendola, M., Zingale, A., Baccarini, A., Lazzari, G., Galli, C., & Naldini, L. (2007) · Nature Biotechnology · doi:10.1038/nbt1372 · Cited by 556
“The threshold requirement may be a result of the limited RNAi machinery available within a cel”
BackgroundHuntington disease: new insights into molecular pathogenesis and therapeutic opportunities
Tabrizi, S. J., Flower, M. D., Ross, C. A., & Wild, E. J. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0389-4 · Cited by 538
Joga, M. R., Zotti, M. J., Smagghe, G., & Christiaens, O. (2016) · Frontiers in Physiology · doi:10.3389/fphys.2016.00553 · Cited by 521
Zhang, Y., Wang, Z., & Gemeinhart, R. A. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.09.015 · Cited by 535
“Moreover, the presence of exogenous artificial miRNAs brings the risk of saturation of RNA processing machinery and cause untoward side effect [81, 170].”
Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs
Khan, A. A., Betel, D., Miller, M. L., Sander, C., Leslie, C. S., & Marks, D. S. (2009) · Nature Biotechnology · doi:10.1038/nbt.1543 · Cited by 534
“and saturation of components of the shRNA or miRNA nuclear export machiner”
Antisense oligonucleotide therapy for neurodegenerative disease
Smith, R. A. (2006) · Journal of Clinical Investigation · doi:10.1172/jci25424 · Cited by 506
“While siRNA to direct selective mRNA degradation using the multicomponent RNA-induced silencing complex (33) is an alternative to DNA oligonucleotides, the more rapid turnover of siRNAs (even when modified to enhance stability) requires infusion of substantially higher dosages to target even relatively rare mRNAs in t…”
BackgroundInfluentialSilencing disease genes in the laboratory and the clinic
Watts, J. K., & Corey, D. R. (2012) · The Journal of Pathology · doi:10.1002/path.2993 · Cited by 470
Gu, S., Jin, L., Zhang, F., Sarnow, P., & Kay, M. A. (2009) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1552 · Cited by 462
Self-citationTargeting long non-coding RNAs in cancers: Progress and prospects
Li, C. H., & Chen, Y. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.05.030 · Cited by 473
MicroRNA history: Discovery, recent applications, and next frontiers
Almeida, M. I., Reis, R. M., & Calin, G. A. (2011) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2011.03.009 · Cited by 466
“[109] Grimm D, Streetz KL, Jopling CL, Storm TA, Pandey K, Davis CR, Marion P, Salazar F, Kay MA.”
Editing the epigenome: technologies for programmable transcription and epigenetic modulation
Thakore, P. I., Black, J. B., Hilton, I. B., & Gersbach, C. A. (2016) · Nature Methods · doi:10.1038/nmeth.3733 · Cited by 451
Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides
Juliano, R., Alam, M. R., Dixit, V., & Kang, H. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn342 · Cited by 429
Clinical experiences with systemically administered siRNA-based therapeutics in cancer
Zuckerman, J. E., & Davis, M. E. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4685 · Cited by 424
Fate tracing of mature hepatocytes in mouse liver homeostasis and regeneration
Malato, Y., Naqvi, S., Schürmann, N., Ng, R., Wang, B., Zape, J., Kay, M. A., Grimm, D., & Willenbring, H. (2011) · Journal of Clinical Investigation · doi:10.1172/jci59261 · Cited by 434
Self-citationDiFiglia, M., Sena-Esteves, M., Chase, K., Sapp, E., Pfister, E., Sass, M., Yoder, J., Reeves, P., Pandey, R. K., Rajeev, K. G., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708285104 · Cited by 415
Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives
Poller, W., Dimmeler, S., Heymans, S., Zeller, T., Haas, J., Karakas, M., Leistner, D.-M., Jakob, P., Nakagawa, S., Blankenberg, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx165 · Cited by 408
MicroRNA Replacement Therapy for miR-145 and miR-33a Is Efficacious in a Model of Colon Carcinoma
Ibrahim, A. F., Weirauch, U., Thomas, M., Grünweller, A., Hartmann, R. K., & Aigner, A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4645 · Cited by 400
“saturation of various cellular factors, which are required for the processing of small RNAs and whose saturation can result in lethal effects (44), is not an issue here because chemically synthesized mature miRNAs do not require cellular processing prior to RISC incorporation.”
RNA-Based Therapeutics: From Antisense Oligonucleotides to miRNAs
Bajan, S., & Hutvagner, G. (2020) · Cells · doi:10.3390/cells9010137 · Cited by 393
MicroRNAs in Disease and Potential Therapeutic Applications
Soifer, H. S., Rossi, J. J., & Sætrom, P. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300311 · Cited by 394
Systematic comparison of CRISPR/Cas9 and RNAi screens for essential genes
Morgens, D. W., Deans, R. M., Li, A., & Bassik, M. C. (2016) · Nature Biotechnology · doi:10.1038/nbt.3567 · Cited by 401
“For example, certain genes would be expected to exhibit an effect on growth in the presence of persistent DNA damage 4,10,25–27 or interference with miRNA processing 11,12 due to Cas9 nuclease activity or shRNA expression, respectively.”
Heidel, J. D., Yu, Z., Liu, J. Y.-C., Rele, S. M., Liang, Y., Zeidan, R. K., Kornbrust, D. J., & Davis, M. E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701458104 · Cited by 382
miR-122, a paradigm for the role of microRNAs in the liver
Girard, M., Jacquemin, E., Munnich, A., Lyonnet, S., & Henrion-Caude, A. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.01.019 · Cited by 375
Bramsen, J. B., Laursen, M. B., Nielsen, A. F., Hansen, T. B., Bus, C., Langkjær, N., Babu, B. R., Højland, T., Abramov, M., Van Aerschot, A., et al. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp106 · Cited by 369
“This type of competition between exogenous RNAi substrates and endogenous miRNAs has been observed both in cell culture (53) and in vivo ( 54 ).”
BackgroundStructure and activity of putative intronic miRNA promoters
Monteys, A. M., Spengler, R. M., Wan, J., Tecedor, L., Lennox, K. A., Xing, Y., & Davidson, B. L. (2010) · RNA · doi:10.1261/rna.1731910 · Cited by 367
“1 (Lewis et al. 2005; Grimson et al. 2007) for predicted miR-128-2 targets that may be relevant to ALL.”
BackgroundArtificial MicroRNAs as siRNA Shuttles: Improved Safety as Compared to shRNAs In vitro and In vivo
Boudreau, R. L., Martins, I., & Davidson, B. L. (2009) · Molecular Therapy · doi:10.1038/mt.2008.231 · Cited by 359
Genome-scale measurement of off-target activity using Cas9 toxicity in high-throughput screens
Morgens, D. W., Wainberg, M., Boyle, E. A., Ursu, O., Araya, C. L., Tsui, C. K., Haney, M. S., Hess, G. T., Han, K., Jeng, E. E., et al. (2017) · Nature Communications · doi:10.1038/ncomms15178 · Cited by 360
The role of microRNAs in cancer: No small matter
Wiemer, E. A. C. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.04.002 · Cited by 342
RNA Interference: From Basic Research to Therapeutic Applications
Kurreck, J. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200802092 · Cited by 335
siRNA Conjugate Delivery Systems
Jeong, J. H., Mok, H., Oh, Y.-K., & Park, T. G. (2009) · Bioconjugate Chemistry · doi:10.1021/bc800278e · Cited by 338
Boudreau, R. L., McBride, J. L., Martins, I., Shen, S., Xing, Y., Carter, B. J., & Davidson, B. L. (2009) · Molecular Therapy · doi:10.1038/mt.2009.17 · Cited by 339
Regulation of MicroRNA Biogenesis: A miRiad of mechanisms
Davis, B. N., & Hata, A. (2009) · Cell Communication and Signaling · doi:10.1186/1478-811x-7-18 · Cited by 336
“Furthermore, saturation of the exportin-5 machinery is known to contribute to the toxicity in liver resulting from high expression of shRNA in mouse [144].”
Therapeutic Oligonucleotides: State of the Art
Smith, C. I. E., & Zain, R. (2019) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021050 · Cited by 323
Huntingtin Lowering Strategies for Disease Modification in Huntington’s Disease
Tabrizi, S. J., Ghosh, R., & Leavitt, B. R. (2019) · Neuron · doi:10.1016/j.neuron.2019.01.039 · Cited by 337
RNAi-based drug design: considerations and future directions
Tang, Q., & Khvorova, A. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00912-9 · Cited by 282
“37).”
MicroRNA biogenesis: regulating the regulators
Finnegan, E. F., & Pasquinelli, A. E. (2013) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2012.738643 · Cited by 311
“Saturation of this transporter by the expression of artificial short hairpins can impair endogenous precursor miRNA transport and, thus, maturation, leading to toxicity in mice (Grimm et al., 2006).”
BackgroundRecent Advances in miRNA Delivery Systems
Dasgupta, I., & Chatterjee, A. (2021) · Methods and Protocols · doi:10.3390/mps4010010 · Cited by 307
MicroRNAs in idiopathic pulmonary fibrosis
Pandit, K. V., Milosevic, J., & Kaminski, N. (2011) · Translational Research · doi:10.1016/j.trsl.2011.01.012 · Cited by 311
“Because microRNAs have multiple targets and affect diverse pathways, their perturbation may lead to unexpected adverse effects as well as predictable side effects such as the fatal oversaturation of their metabolic pathways.(107) This is where focusing on replenishing highly expressed microRNAs that are only inhibited…”
BackgroundLiposome-based drug co-delivery systems in cancer cells
Zununi Vahed, S., Salehi, R., Davaran, S., & Sharifi, S. (2017) · Materials Science and Engineering: C · doi:10.1016/j.msec.2016.11.073 · Cited by 307
A Rapid and Scalable System for Studying Gene Function in Mice Using Conditional RNA Interference
Premsrirut, P. K., Dow, L. E., Kim, S. Y., Camiolo, M., Malone, C. D., Miething, C., Scuoppo, C., Zuber, J., Dickins, R. A., Kogan, S. C., et al. (2011) · Cell · doi:10.1016/j.cell.2011.03.012 · Cited by 315
“Transgenic shRNAs Do Not Impair Normal MicroRNA Processing Studies suggest that high levels of shRNA expression can cause saturation of the miRNA processing machinery (Grimm et al., 2006).”
MicroRNAs in Heart Failure: From Biomarker to Target for Therapy
Vegter, E. L., van der Meer, P., de Windt, L. J., Pinto, Y. M., & Voors, A. A. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.495 · Cited by 303
Engineering RNA for Targeted siRNA Delivery and Medical Application
Guo, P., Coban, O., Snead, N. M., Trebley, J., Hoeprich, S., Guo, S., & Shu, Y. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.03.008 · Cited by 300
“A fundamental study has indicated that high levels of shRNA, a precursor molecule to siRNA, expressed by adeno-associated virus type 8 can cause severe liver toxicity and mortality in mice [193].”
A status report on RNAi therapeutics
Vaishnaw, A. K., Gollob, J., Gamba-Vitalo, C., Hutabarat, R., Sah, D., Meyers, R., de Fougerolles, T., & Maraganore, J. (2010) · Silence · doi:10.1186/1758-907x-1-14 · Cited by 297
“Sequence-independent off-target effects refer to either saturation of the endogenous RISC machinery [38,39] or to the immunostimulatory potential of siRNAs [48].”
BackgroundThe canonical Wnt signalling pathway and its APC partner in colon cancer development
Schneikert, J., & Behrens, J. (2007) · Gut · doi:10.1136/gut.2006.093310 · Cited by 290
Silencing of HIV-1 with RNA Interference: a Multiple shRNA Approach
ter Brake, O., Konstantinova, P., Ceylan, M., & Berkhout, B. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.07.007 · Cited by 293
“Recently, it was shown that expression of shRNAs led to fatality in mice due to oversaturation of the mi/siRNA pathways [39].”
BackgroundRNA interference against viruses: strike and counterstrike
Haasnoot, J., Westerhout, E. M., & Berkhout, B. (2007) · Nature Biotechnology · doi:10.1038/nbt1369 · Cited by 295
“Saturating concentrations of siRNA/shRNAs may interfere with cellular miRNA processing and function; this has been shown to have potentially fatal consequences for mice treated with a viral vector overexpressing shRNAs in the live”
BackgroundThe Loop Position of shRNAs and Pre-miRNAs Is Critical for the Accuracy of Dicer Processing In Vivo
Gu, S., Jin, L., Zhang, Y., Huang, Y., Zhang, F., Valdmanis, P. N., & Kay, M. A. (2012) · Cell · doi:10.1016/j.cell.2012.09.042 · Cited by 285
“To further support our conclusion through use of a different promoter, we compared a shRNA directed against human a-antitrypsin (sh-hAAT-25) under the transcriptional control of either the U6 or H1 promoter (Grimm et al., 2006).”
BackgroundSelf-citationAction and Reaction: The Biological Response to siRNA and Its Delivery Vehicles
Kanasty, R. L., Whitehead, K. A., Vegas, A. J., & Anderson, D. G. (2012) · Molecular Therapy · doi:10.1038/mt.2011.294 · Cited by 279
RNAi‐based therapeutics–current status, challenges and prospects
Tiemann, K., & Rossi, J. J. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900023 · Cited by 283
Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity
Janas, M. M., Schlegel, M. K., Harbison, C. E., Yilmaz, V. O., Jiang, Y., Parmar, R., Zlatev, I., Castoreno, A., Xu, H., Shulga-Morskaya, S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-02989-4 · Cited by 279
RNAi and small interfering RNAs in human disease therapeutic applications
Lares, M. R., Rossi, J. J., & Ouellet, D. L. (2010) · Trends in biotechnology · doi:10.1016/j.tibtech.2010.07.009 · Cited by 277
Castanotto, D., Sakurai, K., Lingeman, R., Li, H., Shively, L., Aagaard, L., Soifer, H., Gatignol, A., Riggs, A., & Rossi, J. J. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm543 · Cited by 269
“(19) reported that some shRNA sequences were able to block the activity of the liverspecific miR122 and additionally caused severe liver toxicity and death of some of the treated mice.”
BackgroundCRISPR/Cas9‐mediated genome engineering: An adeno‐associated viral (AAV) vector toolbox
Senís, E., Fatouros, C., Große, S., Wiedtke, E., Niopek, D., Mueller, A., Börner, K., & Grimm, D. (2014) · Biotechnology Journal · doi:10.1002/biot.201400046 · Cited by 260
Self-citationFATP2 is a hepatic fatty acid transporter and peroxisomal very long-chain acyl-CoA synthetase
Falcon, A., Doege, H., Fluitt, A., Tsang, B., Watson, N., Kay, M. A., & Stahl, A. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00226.2010 · Cited by 249
Self-citationNanoparticle-based delivery of small interfering RNA: challenges for cancer therapy
Gulino, A. (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s23696 · Cited by 258
“The components of the cellular machinery involved in gene silencing could be less accessible to miRNAs entering the natural cellular pathway.(47,54,55) Intact RNAi machinery is clearly essential for mammalian cells, as suggested by the early embryonic lethality of Dicer knockouts.”
Promoterless gene targeting without nucleases ameliorates haemophilia B in mice
Barzel, A., Paulk, N. K., Shi, Y., Huang, Y., Chu, K., Zhang, F., Valdmanis, P. N., Spector, L. P., Porteus, M. H., Gaensler, K. M., et al. (2015) · Nature · doi:10.1038/nature13864 · Cited by 257
Self-citationHeme oxygenase-1 in tumor biology and therapy
Was, H., Dulak, J., & Jozkowicz, A. (2010) · Current Drug Targets · doi:10.2174/1389450111009011551 · Cited by 259
“[302] Grimm D, Streetz KL, Jopling CL, et al.”
BackgroundCurrent Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma
Padfield, E., Ellis, H. P., & Kurian, K. M. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00005 · Cited by 245
“In RNA studies, AAV/shRNA vectors were found to be severely toxic, and caused fatality in 64% of mice due to oversaturation of RNAi pathways (82, 83).”
Background
Metadata
- Authors
- Grimm, D., Streetz, K. L., Jopling, C. L., Storm, T. A., Pandey, K., Davis, C. R., Marion, P., Salazar, F., & Kay, M. A.
- Affiliations
- Stanford Medicine (US)
- Universitätsklinikum Aachen (DE)
- Corresponding author
- Kay, Mark A.
- Venue
- Nature
- Published
- 2006-05
- Volume
- 441
- Issue
- 7092
- Pages
- 537-541
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1971643509
- Cited by
- 1,677
- References
- 31
- Citations by year
- 2026: 27 · 2025: 32 · 2024: 49 · 2023: 35 · 2022: 57 · 2021: 36 · 2020: 45 · 2019: 54 · 2018: 54 · 2017: 60 · 2016: 75 · 2015: 94 · 2014: 92 · 2013: 121 · 2012: 121
- FWCI
- 57.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- RWTH Publications (RWTH Aachen) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- RNA interference, shRNA, microRNA, XPO5, hepatotoxicity, liver injury, AAV8 vector, siRNA delivery, karyopherins, post-transcriptional gene silencing, mice, gene silencing therapy, dose-dependent toxicity
- MeSH terms
- Animals, Hepatitis B virus, Humans, Liver, Liver Regeneration, Mice, Transgenic, Nucleic Acid Conformation, RNA, Survival Analysis, Karyopherins, RNA Interference, MicroRNAs, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.